Kura Oncology (NASDAQ:KURA) Reaches New 12-Month Low - Here's What Happened

Kura Oncology, Inc. (NASDAQ:KURA - Get Free Report)'s share price hit a new 52-week low during trading on Tuesday . The stock traded as low as $8.34 and last traded at $8.56, with a volume of 96391 shares. The stock had previously closed at $8.51.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on KURA. StockNews.com cut Kura Oncology from a "hold" rating to a "sell" rating in a research report on Wednesday, November 20th. Bank of America reduced their target price on shares of Kura Oncology from $36.00 to $29.00 and set a "buy" rating for the company in a research note on Friday, November 22nd. Stifel Nicolaus cut shares of Kura Oncology from a "buy" rating to a "hold" rating and cut their price target for the stock from $26.00 to $19.00 in a report on Monday, October 14th. TD Cowen reaffirmed a "buy" rating on shares of Kura Oncology in a research report on Thursday, November 21st. Finally, HC Wainwright increased their price objective on Kura Oncology from $32.00 to $37.00 and gave the company a "buy" rating in a report on Thursday, November 21st. One analyst has rated the stock with a sell rating, one has issued a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Kura Oncology presently has a consensus rating of "Moderate Buy" and an average target price of $29.86.

Kura Oncology Price Performance

The firm has a market capitalization of $635.33 million, a P/E ratio of -3.46 and a beta of 0.81. The business's 50-day simple moving average is $12.29 and its 200 day simple moving average is $17.17. The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02.

Institutional Trading of Kura Oncology

Institutional investors have recently added to or reduced their stakes in the business. nVerses Capital LLC purchased a new stake in Kura Oncology during the 3rd quarter valued at about $25,000. The Manufacturers Life Insurance Company increased its stake in shares of Kura Oncology by 5.4% in the second quarter. The Manufacturers Life Insurance Company now owns 38,536 shares of the company's stock worth $793,000 after buying an additional 1,976 shares during the period. Hsbc Holdings PLC raised its holdings in Kura Oncology by 13.4% during the 2nd quarter. Hsbc Holdings PLC now owns 18,300 shares of the company's stock valued at $374,000 after buying an additional 2,167 shares during the last quarter. JPMorgan Chase & Co. boosted its position in Kura Oncology by 0.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 409,241 shares of the company's stock valued at $7,997,000 after buying an additional 3,092 shares during the period. Finally, Bellevue Group AG grew its holdings in Kura Oncology by 36.0% in the 3rd quarter. Bellevue Group AG now owns 13,600 shares of the company's stock worth $266,000 after acquiring an additional 3,600 shares during the last quarter.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.